The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Six Monthly Return

27 Jan 2020 13:51

RNS Number : 0366B
Horizon Discovery Group plc
27 January 2020
 

Horizon Discovery Group plc

27 January 2020

 

 

Horizon Discovery Group plc

Block Listing Six Monthly Return

27 January 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon") provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

Name of applicant:

Horizon Discovery Group plc

 

Name of scheme(s):

a) Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme

b) Horizon Discovery Group plc Long Term Incentive Plan

c) Horizon Discovery 2014 Sharesave Scheme

d) Horizon Discovery Group plc US Employee Stock Purchase Plan

 

Period of return (from / to):

From 26 July 2019 to 25 January 2020

Number of securities admitted and date of admission

Total of 3,000,000 ordinary shares of 1p each, admission date 26 July 2017, split:

a) 1,398,000 

b) 1,392,000

c) 110,000

d) 100,000

Further 500,000 ordinary shares of 1p each, admission date 27 July 2018, split:

a) 0

b) 150,000

c) 150,000

d) 200,000

 

Balance of unallotted securities under schemes from previous return:

Total of 1,723,992 ordinary shares of 1p each, split:

a) 609,750

b) 912,893

c) 85,760

d) 115,589

 

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

 

Further 1,500,000 ordinary shares of 1p each, admission date 28 October 2019, split:

a) 0

b) 500,000

c) 500,000

d) 500,000

 

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 240,348 ordinary shares of 1p each, split:

a) 7,325

b) 60,217

c) 17,789

d) 155,017

 

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 2,983,644 ordinary shares of 1p each, split:

a) 602,425

b) 1,352,676

c) 567,971

d) 460,572

 

ENDS

 

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580

 

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Tom Ballard / Duncan Monteith

Tel: +44 (0) 207 260 1000

Consilium Strategic Communications (UK Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

 

Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. 646-277-1282

Email: horizondisovery@icrinc.com

 

 

 

About Horizon Discovery Group plc www.horizondiscovery.com

 

Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market - supporting scientists on the path from research to therapy.

 

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.

 

Horizon's solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.

 

The Company's customers include many of the world's foremost academic institutes, global biopharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables Horizon to focus efforts on development of innovative solutions that not only differentiate the Company's offering, but also fuel development of the next wave of precision medicines.

 

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRUBSORRWUAUAR
Date   Source Headline
25th Mar 20157:00 amRNSHorizon Discovery awarded AMSCI grant
24th Mar 20157:00 amRNSNotice of Preliminary Results
23rd Mar 20157:00 amRNSHorizon Discovery and ArcherDX Sign OEM Agreement
18th Mar 201510:39 amRNSAdditional Listing
11th Mar 20157:00 amRNSHorizon Provides Genomic Standards To CRUK
18th Feb 20157:00 amRNSInnovate UK funding award
11th Feb 20154:27 pmRNSAdditional Listing
5th Feb 201512:21 pmRNSAdditional Listing
2nd Feb 20157:00 amRNSHorizon Discovery Selected as Core Facility
27th Jan 201512:00 pmRNSAdditional Listing
23rd Jan 20154:46 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSRevenues expected to be ahead of consensus by 7%
15th Jan 20157:00 amRNSHolding(s) in Company
8th Jan 20157:00 amRNSAcquisition of Haplogen Genomics GmbH
30th Dec 20147:00 amRNSHorizon Discovery Group Signs Agreement for $810K
22nd Dec 20144:49 pmRNSAdditional Listing
19th Dec 20146:23 pmRNSHolding(s) in Company
8th Dec 20147:00 amRNSLaunch of Gene-Engineered Bioproduction Cell Line
26th Nov 20143:09 pmRNSHolding(s) in Company
24th Nov 20147:00 amRNSHorizon Enter Agreement with Adarza BioSystems
19th Nov 201412:26 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNS$750,000 contract win from top ten pharma
3rd Nov 20147:00 amRNSAppoints Dr David Smoller as an Executive Director
15th Oct 20147:00 amRNSHorizon CombinatoRx Wins Contract
6th Oct 20143:14 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Oct 20147:00 amRNSCo-Exclusive Commercial Agreement Signed
29th Sep 20147:00 amRNSAcquires Sage Labs Inc. for $48M (£29M)
25th Sep 201412:30 pmRNSAdditional Listing
25th Sep 20147:00 amRNS$1.2 million Master Services Agreement
23rd Sep 20147:00 amRNSInterim Results for Six Months Ended 30 June 2014
17th Sep 20144:34 pmRNSHolding(s) in Company
15th Sep 20145:29 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th Sep 201410:17 amRNSAdditional Listing
3rd Sep 20147:00 amRNSNotice of Interim Results
5th Aug 20147:00 amRNSCRISPR Experts Join Scientific Advisory Board
28th Jul 20143:57 pmRNSAdditional Listing
25th Jul 20147:00 amRNSHZD sign Collaboration Agreement with Otsuka
23rd Jul 20147:00 amRNSTrading Update
3rd Jul 20147:00 amRNSLicenses AAV Gene Delivery Technology
19th Jun 201410:48 amRNSDirector/PDMR Shareholding
17th Jun 20143:35 pmRNSAdditional Listing
16th Jun 20147:00 amRNSTSB Grant for next generation cancer diagnostics
12th Jun 20147:00 amRNSLicenses CRISPR Technology from Broad Institute
11th Jun 201412:11 pmRNSDirector/PDMR Shareholding
9th Jun 20147:00 amRNSAppointment of two Non-Executive Directors
2nd Jun 20147:00 amRNSCompletion of Acquisition of CombinatoRx
15th May 20147:00 amRNSAcquisition
8th May 20147:00 amRNSHolding in Company
8th May 20147:00 amRNSLicenses Gene Editing Technology from ERS Genomics
6th May 20145:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.